fda warning letter bpc-157 2024 2025 letters for medical device companies Explained FDA Enforcement In 2025: What

DSIP is not FDA-approved and not scheduled

Stable gastric pentadecapeptide BPC 157 [129,130,131,132,133,134,135,136,137,138,139,140,141,142,168] has proven its effectiveness in resolving these harmful events, counteracting brain, heart, lung, liver, kidney, and gastrointestinal tract lesions, arrhythmias, hemorrhage (brain, lung), and thrombosis, peripherally and centrally, intracranial hypertension, portal hypertension, caval hypertension, and aortic hypotension, which are markedly attenuated or even eliminated, with advanced Virchow triad circumstances fully reversed

doi: 10.1016/0024-3205(82)90578-1

FDA & Legal Disclaimer All products sold by Legionary Peptides are intended strictly for laboratory research and industrial use only

CMS says that it wants to end spending that duplicates resources available through other federal and directly tied to healthcare services